Novel Substituted Pyridinyl Imidazoles as Potent Anticytokine Agents with Low Activity against Hepatic Cytochrome P450 Enzymes
作者:Stefan A. Laufer、Gerd K. Wagner、Dunja A. Kotschenreuther、W. Albrecht
DOI:10.1021/jm030766k
日期:2003.7.1
been linked to the liver toxicity observed for model p38 inhibitors, was very efficiently reduced through introduction of a tetramethylpiperidine substituent at the 1 position of the imidazole nucleus. Combination of both structural features provided 14c (p38: 0.34 microM, inhibition of CYP1A2 0%, 2C9 2.6%, 2C19 7.6% at 10 microM), which was selected for further development.
制备了一系列p38 MAP(有丝分裂原活化蛋白)激酶的多取代吡啶-4-基咪唑抑制剂,作为小分子抗细胞因子药物和候选药物,用于治疗慢性炎性疾病。评估了吡啶基和咪唑部分的取代基对选择性抑制p38的贡献,而没有伴随的细胞色素P450相互作用。将1-苯基乙基(7e,p38:IC(50)0.38 microM)或乙酰基取代基放置在几个2-氨基吡啶咪唑的环外氮原子上导致鉴定出有效的p38抑制剂,该抑制剂超过了起始铅ML 3375(p38:IC (50)0.63 microM)效能。初步的模型研究将7e的增强生物活性与其1-苯基乙基氨基侧链和靠近p38接头区域的疏水口袋之间的新型相互作用相关。该系列中最活跃的p38抑制剂在功能性PBMC(外周血单个核细胞)和全血测定中保持了其功效。此外,与在模型p38抑制剂中观察到的肝毒性有关的细胞色素P450相互作用,通过在咪唑核的1位上引入四甲基哌啶取代基而非常有效